Hutchinson's tissue oxygenation monitor gets EU nod
This article was originally published in Clinica
Executive Summary
Hutchinson Technology has launched its InSpectra StO2 spot check (model 300) in Europe, after CE marking the product. It is designed to measure tissue oxygenation levels in patients with circulatory distress in emergency and critical care environments, and consists of a hand-held device and noninvasive sensor employing near infrared spectroscopy that is placed on the thumb. Patients with low levels are at risk of poor clinical outcomes; once identified, they can then be continuously monitored with the firm's InSpectra StO2 tissue oxygenation monitor (model 650) and treated accordingly. The Hutchinson, Minnesota-based firm has also filed a 510(k) application for the StO2 spot check test with the US FDA.